Description
Key facts
Purity:>70% SDS-PAGE,
Expression system:HEK 293 cells,
Tags:His tag C-Terminus,
Applications:SDS-PAGE, FuncSSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Biologically active:Yes,
Biological activity:Assay Conditions:50 μL reaction mix (50 mM HEPES pH 7.4, 50 mM NaCl, 200 μM CaCl2, 0.05% Tween-20, 0.1% BSA, and 0–1500 ng ab198753) is added to wells precoated with LDLR Ectodomain. Incubate for 2 hr. Add streptavidin-labeled HRP and incubate 1 hour. Finally, add HRP chemiluminescent substrates and read luminescence.,
Conjugation:Biotin,
Accession:Q8NBP7,
Animal free:No,
Carrier free:No,
Species:Human,
Storage buffer:pH: 7.4Constituents: 20% Glycerol (glycerin, glycerine), 0.64% Sodium chloride, 0.48% Tris, 0.02% Potassium chloride
Product details:
Useful for studying protein binding and screening small molecules for drug discovery.
Properties and Storage Information:
Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--80°C, Appropriate long-term storage conditions--80°C, Storage information-Avoid freeze / thaw cycle
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein responsible for the regulation of cholesterol levels by binding to low-density lipoprotein receptors (LDLR) on hepatocytes. This interaction marks the LDLRs for degradation reducing the liver's ability to clear LDL cholesterol from the blood. PCSK9 has a molecular weight of approximately 74 kDa. The protein is mainly expressed in the liver but is also found in the intestine and kidneys. PCSK9 is referred to as NARC-1 standing for neural apoptosis-regulated convertase 1 highlighting its role in the liver's cholesterol management system.
Biological function summary
PCSK9 influences cholesterol homeostasis by its important role in degrading LDL receptors. It functions independently rather than as part of larger protein complexes. PCSK9 gains particular interest in therapeutic contexts where its inhibition can lead to increased LDLR levels and enhanced clearance of LDL cholesterol. Biotinylated PCSK9 and mouse PCSK9 variants provide significant tools for experimental study. Kits such as the PCSK9 ELISA kit enable detailed measurement of PCSK9 levels in blood samples providing insights into cholesterol metabolism dynamics.
Pathways
PCSK9 operates within the lipid metabolism pathway and the cholesterol biosynthesis pathway. The protein's activity affects the fate of LDL cholesterol within these pathways. It interacts with proteins such as apolipoprotein B (ApoB) which plays a central role in the structural component of LDL particles. The modulation of these pathways by PCSK9 highlights the significance of its function in maintaining cardiovascular health and managing cholesterol levels.
PCSK9 is closely linked to hypercholesterolemia and coronary artery disease. Mutations in PCSK9 can lead to autosomal dominant hypercholesterolemia due to its effect on LDL receptor degradation. Other proteins such as ApoB and LDLR are involved in these conditions tightly interacting with PCSK9's regulatory function. A better understanding of PCSK9's role offers potential therapeutic targets for cardiovascular disease interventions especially through the development of PCSK9 antibodies and PCSK9 assays that adjust cholesterol levels.
